Annette T. New v. Armour Pharmaceutical Company

58 F.3d 445, 95 Cal. Daily Op. Serv. 4766, 95 Daily Journal DAR 8185, 1995 U.S. App. LEXIS 15329, 1995 WL 368871
CourtCourt of Appeals for the Ninth Circuit
DecidedJune 22, 1995
Docket93-56023
StatusPublished
Cited by1 cases

This text of 58 F.3d 445 (Annette T. New v. Armour Pharmaceutical Company) is published on Counsel Stack Legal Research, covering Court of Appeals for the Ninth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Annette T. New v. Armour Pharmaceutical Company, 58 F.3d 445, 95 Cal. Daily Op. Serv. 4766, 95 Daily Journal DAR 8185, 1995 U.S. App. LEXIS 15329, 1995 WL 368871 (9th Cir. 1995).

Opinion

NOONAN, Circuit Judge:

Annette T. New, the successor in interest of Joseph J. New, (New), deceased, appeals from the judgment of the district court dismissing New’s action against Armour Pharmaceutical Company (Armour). The single issue on appeal is when the California statute of limitations begins to run on causes of action for the wrongful infliction of AIDS. Holding that the issue cannot be decided on the pleadings, we return the case to the district court.

PROCEEDINGS

On January 19, 1993, New, a citizen of California, filed suit against Armour in Los Angeles County Superior Court. Armour, a Delaware corporation, removed the case to the federal district court on the ground of diversity of citizenship. New alleged the following:

New was born October 22, 1935. In his sixth year he experienced episodes of abnormal bleeding, and in 1961 he was diagnosed as a Type A hemophiliac; he was thereafter successfully treated with blood-coagulating products.

Armour and three other companies were manufacturers and marketers of an agent for the treatment of Type A hemophilia known generically as Factor VIII. Factor VIII is a concentrated, freeze-dried form of coagulating human blood protein and is manufactured from pooled donations of human blood plasma obtained, for a given manufacturing lot, from as many as 20,000 donors. It was marketed for use of patients in a hospital environment, in a physician’s office, or in a home care program as an effective product for treatment of Type A hemophilia. New was treated with Factor VIII produced by Armour on May 10, 1981, July 3,1983, March 3, 1984, and June 3, 1984.

In 1988 New, on the advice of his physician, underwent tests to determine if there was present in his blood antibodies believed to indicate the presence of the Human Immunodeficiency Virus (HIV). New tested positive.

*447 On information and belief, New farther alleged that as early as July 1982, and no later than mid-January 1983, Armour and the three other manufacturers had reason to know that they were collecting blood plasma for Factor VIII from donors who were representative of the population groups known to exhibit high risk for Acquired Immunodeficiency Syndrome (AIDS); that users of Factor VIII had developed AIDS under circumstances not involving on their part any of the other forms of human activity suspected of being involved in the transmission of AIDS; that the agency for transmitting AIDS was blood-borne and probably a virus; that such agent appeared to be capable of surviving the manufacturing process by which Factor VIII was made; that a reliable and inexpensive test existed for detecting Hepatitis B virus in humans and that there was a high degree of correlation between infection with this virus and infection with AIDS so that blood donors with AIDS could be screened out; and that prior to July 1983 Armour and the other manufacturers had sufficient information to warn physicians, pharmacists, hospitals and other purchasers of Factor VIII of the risk of contamination, but that no physician or health care professional treating New informed him prior to 1985 of such risk and that he is informed and believes that Armour did not communicate such information or provide any warnings to physicians who treated him prior to late 1984. He further alleged that he learned most of what he knows about the risk of the contamination of Factor VIII by HIV within the past year. If he had been aware of the information he would not have consented to infusions of Factor VIII between July 1, 1983 and June 30, 1984 but would have used other means of treating his hemophilia involving a lower risk of transmission of HIV. During this period he became infected with HIV through infusion of Factor VIII.

New further alleged that infection with HIV “leads almost invariably” to the development of AIDS, itself “almost invariably a terminal disease” within an average of eleven years from the time of infection with HIV. He recited a number of facts occurring “within” the year preceding the filing of his complaint that indicated serious deterioration of his health, and he noted that on January 17, 1992 he had stopped work “as the result of the progressive effect of these conditions.” He died after the decision of the district court and prior to the argument of this appeal.

The complaint set out the following causes of action: (1) negligent failure of Armour to warn about the risk of HIV in Factor VIII; (2) negligent manufacture of Factor VIII by Armour and failure to adequately screen and test blood donors; (3) negligent failure to timely implement heat treatment of Factor VIII; (4) negligent failure to recall contaminated Factor VIII already in the hands of physicians; (5) conspiracy with the other manufacturers of Factor VIII to conceal the risk of contamination and to avoid recall of the dangerous product; (6) intentional failure by Armour to warn; (7) intentional failure to screen and test; (8) intentional failure to heat treat the product; and (9) intentional failure to recall Factor VIII.

Armour moved to dismiss under Federal Rule of Civil Procedure 12(b) on the grounds that New’s complaint was barred by the one-year statute of limitations set out in California Code of Civil Procedure § 340(3) and, to the extent applicable, § 338(d). Noting that New tested positive in 1988, the district court held: “When plaintiff tested positive for HIV ... he knew of his infection with HIV and suspected or should have suspected that his infection was caused by something done wrong to him. Such knowledge, especially when combined with the fact that the plaintiffs health further deteriorated more than a year before he filed his complaint as a result of the progressive impairment of his autoimmune system from his infection with HIV (Complaint at ¶ 24), is sufficient to start the statute running.” The district court added that, since New could not amend his complaint “without contradicting the allegations in his original complaint which establish that the statute has run,” his complaint must be dismissed with prejudice. On June 7, 1993, judgment was entered in favor of Armour, and Armour was given its costs. Appeal was taken.

*448 ANALYSIS

In a medical malpractice action against a hospital and blood bank for a transfusion with tainted blood, it was assumed arguendo that the plaintiffs injury was deemed to have occurred when a blood test revealed that he had HIV. Katz v. Children’s Hosp., 28 F.3d 1520, 1523-24 (9th Cir.1994); there was neither a holding nor even a discussion relating infection with HIV to AIDS. Katz does not help us here.

This case is controlled by California law as set out in Jolly v. Eli Lilly & Co., 44 Cal.3d 1103, 245 Cal.Rptr. 658, 751 P.2d 923 (1988), understood in terms of its facts and the cases it cites with approval. In this authoritative exposition of the California approach to the statute of limitations governing personal injury torts, the Supreme Court of California said:

In Davies v. Krasna

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Waage v. Cutter Biological Division of Miles Laboratories, Inc.
926 P.2d 1145 (Alaska Supreme Court, 1996)

Cite This Page — Counsel Stack

Bluebook (online)
58 F.3d 445, 95 Cal. Daily Op. Serv. 4766, 95 Daily Journal DAR 8185, 1995 U.S. App. LEXIS 15329, 1995 WL 368871, Counsel Stack Legal Research, https://law.counselstack.com/opinion/annette-t-new-v-armour-pharmaceutical-company-ca9-1995.